A case report of targeted therapy with apatinib in a patient with recurrent high grade glioma. Issue 22 (June 2018)

• Record Type: Journal Article
• Authors: Ding, Xiuping; Sun, Jujie; Fan, Tingyong; Li, Baosheng
• Other Names: Parekh. Parag section editor.
• Is Part Of: Medicine. Volume 97:Issue 22(2018)
• Publication Date: 2018-06
• Subjects: angiogenesis -- apatinib -- bevacizumab -- high grade glioma -- vascular endothelial growth factor; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000010859
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Despite the approval of antiangiogenic therapy for high grade glioma (HGG) patients, survival benefits are still limited. New treatment plans have always been developed to improve the survival. Patient concerns: A 26-year-old woman was admitted to our hospital for distending pain of head and eye. Diagnoses: Resonance imaging (MRI) revealed a large spherical heterogeneously enhancing, mixed cystic and solid mass in the right frontal region, and the midline shifted. Intervention: The patient received apatinib therapy for positive vascular endothelial growth factor. Outcomes: A partial response was observed after 4 weeks and remains sustained until now. Lessons: It suggests that apatinib might be a feasible option for the treatment in advanced HGG patients or patients with poor physical condition.